| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 12/24/2014 | CN104231086A 双功能融合蛋白及其制备方法和用途 Bifunctional fusion protein and its preparation and use |
| 12/24/2014 | CN104231084A 抗人cd52免疫球蛋白 Cd52 anti-human immunoglobulin |
| 12/24/2014 | CN104231083A 抗胰高血糖素受体的抗体及其用途 Anti-glucagon receptor antibody and uses thereof |
| 12/24/2014 | CN104231082A 用于治疗骨疾病和病症的针对rank-l的氨基酸序列以及包括其的多肽 For rank-l amino acid sequence for the treatment of bone diseases and disorders as well as a polypeptide including |
| 12/24/2014 | CN104231080A 全人源抗人白介素17a单链抗体 Fully human anti-human interleukin-17a single-chain antibody |
| 12/24/2014 | CN104231079A 一种靶向bFGF高亲和力受体结合位点的抗体及其应用 BFGF which targets high affinity receptor binding site antibodies and their application |
| 12/24/2014 | CN104231078A 抗-血管内皮生长因子的抗体 Anti - vascular endothelial growth factor antibody |
| 12/24/2014 | CN104231068A 人白细胞介素ii突变体及其应用 Human interleukin ii mutant and its application |
| 12/24/2014 | CN104231061A 一种副溶血弧菌外膜蛋白LptD的制备方法及其应用 One kind of outer membrane proteins of Vibrio parahaemolyticus LptD preparation method and its application |
| 12/24/2014 | CN104231060A 人乳头瘤病毒l1l2衣壳蛋白相互作用位点及其应用 L1l2 human papillomavirus capsid protein interaction sites and applications |
| 12/24/2014 | CN104225620A 生物时间机器技术 Biological time machine technology |
| 12/24/2014 | CN104225610A 与阴离子磷脂和氨基磷脂结合的选定抗体及其治疗用途 With anionic phospholipids and phospholipid binding amino selected antibodies and therapeutic uses |
| 12/24/2014 | CN104225598A microRNA150在治疗动脉粥样硬化中的功能和应用 microRNA150 features and applications in the treatment of atherosclerosis in |
| 12/24/2014 | CN104225597A Mapk信号整合激酶1在治疗动脉粥样硬化中的功能和应用 Mapk kinase 1 signal integrated features and applications in the treatment of atherosclerosis in |
| 12/24/2014 | CN104225594A 抗her2人源化抗体及其相关的抗肿瘤组合物 Anti her2 humanized antibodies and related anti-tumor composition |
| 12/24/2014 | CN104225593A 一种水溶性复合免疫佐剂以及含有该佐剂的疫苗组合物 A water-soluble complex immunological adjuvant and vaccine composition containing the adjuvant |
| 12/24/2014 | CN104225592A 乳腺癌干细胞疫苗及其制备方法与应用 Vaccines and cancer stem cell preparation method and application |
| 12/24/2014 | CN104225591A 一种免疫佐剂及含有该免疫佐剂的疫苗 An immune adjuvant and vaccine containing the immune adjuvant |
| 12/24/2014 | CN104225590A 一种自乳化型油相佐剂及其疫苗组合物和制备方法 The emulsified oil phase adjuvant and vaccine compositions and methods for preparing self- |
| 12/24/2014 | CN104225589A 一种缀合疫苗及其制备方法 One kind of conjugated vaccine and its preparation method |
| 12/24/2014 | CN104225588A b型流感嗜血杆菌结合疫苗的制备方法 Haemophilus influenzae type b vaccine preparation |
| 12/24/2014 | CN104225587A 多价脑膜炎球菌衍生的多糖-蛋白质缀合物及疫苗 Multivalent meningococcal polysaccharide derived - protein conjugates and vaccines |
| 12/24/2014 | CN104225586A 一种含融合蛋白a1d4的结核病亚单位疫苗 A1d4 fusion protein containing tuberculosis subunit vaccine |
| 12/24/2014 | CN104225578A 一种免疫增强剂及其在多克隆抗体制备中的应用 An immune enhancer and its application in the preparation of polyclonal antibodies |
| 12/24/2014 | CN103484411B 禽源大肠杆菌疫苗株(nn株)及其应用 Poultry vaccine strain of Escherichia coli (nn strain) and its application |
| 12/24/2014 | CN103483430B 蛋白a1g_07050在抗立氏立克次体的免疫保护中的应用 Application of protective immunity protein a1g_07050 anti-Rickettsia rickettsii in the |
| 12/24/2014 | CN103251943B 一种制备b型流感嗜血杆菌多糖结合疫苗的方法 A polysaccharide conjugate vaccine prepared by Haemophilus influenzae type b |
| 12/24/2014 | CN103182080B 鸡传染性喉气管炎、鸡痘二联活疫苗 ILTV, fowl pox bivalent vaccine |
| 12/24/2014 | CN102740883B 用于制备旨在预防球虫病的疫苗组合物的佐剂 An adjuvant for the preparation of a vaccine designed to prevent coccidiosis compositions |
| 12/24/2014 | CN102614511B 水貂巴氏杆菌病蜂胶灭活苗 Mink Pasteurellosis propolis inactivated vaccine |
| 12/24/2014 | CN102596999B 识别淀粉样蛋白β的转角结构的抗体 Antibodies recognize amyloid β corner structure |
| 12/24/2014 | CN102458469B 人抗TNF-α抗体的稳定高蛋白质浓度制剂 Human anti-stable high protein concentration formulations TNF-α antibody |
| 12/24/2014 | CN102370978B 温度敏感性乙型肝炎疫苗 Temperature sensitivity of hepatitis B vaccine |
| 12/24/2014 | CN102245639B 抗体制剂 Antibody preparations |
| 12/24/2014 | CN102159240B 基于狂犬病毒的重组免疫避孕组合物及其使用方法 The recombinant rabies virus immune-based compositions and methods of use of contraception |
| 12/23/2014 | US8916616 Multi-functional polymeric materials and their uses |
| 12/23/2014 | US8916541 Synergistic combination of honokiol and modified citrus pectin in cancer therapy |
| 12/23/2014 | US8916519 Influenza A virus vaccines and inhibitors |
| 12/23/2014 | US8916518 Coupling proteins to a modified polysaccharide |
| 12/23/2014 | US8916514 CASB7439 constructs |
| 12/23/2014 | US8916387 Diagnosis and treatment of Alzheimer's disease |
| 12/23/2014 | US8916381 Methods for treatment of cancer |
| 12/23/2014 | US8916379 Mammalian alpha-kinase proteins, nucleic acids and diagnostic and therapeutic uses thereof |
| 12/23/2014 | US8916372 Strain of Salmonella enterica s. typhimurium, its use and a method to obtain a therapeutic vaccine vector |
| 12/23/2014 | US8916371 Recombinant equine herpesvirus-1 vaccine containing mutated glycoprotein C and uses thereof |
| 12/23/2014 | US8916353 Circovirus sequences associated with piglet weight loss disease (PWD) |
| 12/23/2014 | US8916340 Method for identifying and validating dominant T helper cell epitopes using an HLA-DM-assisted class II binding assay |
| 12/23/2014 | US8916211 Method and composition for preventing and treating avian influenza in poultry |
| 12/23/2014 | US8916177 Method for treating premature ejaculation with a botulinum neurotoxin |
| 12/23/2014 | US8916176 Modified parvovirus having enhanced anti-tumor efficacy |
| 12/23/2014 | US8916175 Safer attenuated varicella-zoster virus vaccines with missing or diminished latency of infection |
| 12/23/2014 | US8916174 HIV DNA vaccine regulated by a caev-derived promoter |
| 12/23/2014 | US8916173 Acellular pertussis vaccine |
| 12/23/2014 | US8916172 MVA expressing modified HIV envelope, gag, and pol genes |
| 12/23/2014 | US8916170 Methods of producing antibodies against morphine-heroine |
| 12/23/2014 | US8916169 Enhanced immunogenicity of tumor associated antigens by addition of alphagal epitopes |
| 12/23/2014 | US8916168 Leishmania sterol 24-c-methyltransferase compositions for the prevention, treatment and diagnosis of leishmaniasis |
| 12/23/2014 | US8916167 Treatment and diagnosis of macrophage mediated disease |
| 12/23/2014 | US8916166 Porphyromonas gingivalis polypeptides useful in the prevention of periodontal disease |
| 12/23/2014 | US8916165 Humanized Aβ antibodies for use in improving cognition |
| 12/23/2014 | US8916164 Methods of enhancing adjuvaticity of vaccine compositions |
| 12/23/2014 | US8916163 Method for treating microbial infections |
| 12/23/2014 | US8916162 Botulinum neurotoxin antigenic compositions and methods |
| 12/23/2014 | US8916161 Method of treating or preventing benign prostatic hyperplasia using modified pore-forming proteins |
| 12/23/2014 | US8916160 Compositions and methods for the therapy and diagnosis of influenza |
| 12/23/2014 | US8916159 Selenocysteine mediated hybrid antibody molecules |
| 12/23/2014 | US8916158 Formulation of human antibodies for treating TNF-α associated disorders |
| 12/23/2014 | US8916157 Formulation of human antibodies for treating TNF-α associated disorders |
| 12/23/2014 | US8916156 Isolated egg protein and egg lipid materials, and methods for producing the same |
| 12/23/2014 | US8916155 Method for the treatment of T cell mediated conditions by depletion of ICOS-positive cells in vivo |
| 12/23/2014 | US8916154 Antibodies against delta-5 desaturase and uses thereof |
| 12/23/2014 | US8916153 Purified antibody composition |
| 12/23/2014 | US8916152 S100A4 antibodies and therapeutic uses thereof |
| 12/23/2014 | US8916150 Compositions and methods for enhancing metal ion dependent drug therapies |
| 12/23/2014 | US8916147 Universal donor-derived tolerogenic cells for inducing non-syngeneic transplantation tolerance |
| 12/18/2014 | US20140370497 Metapneumovirus strains and their use in vaccine formulations and as vectors for expression of antigenic sequences |
| 12/18/2014 | US20140370099 Artificial antigen presenting cells having a defined and dynamic shape |
| 12/18/2014 | US20140370086 Sublingual immunotherapy with reduced oral itchiness |
| 12/18/2014 | US20140370059 USE OF mTOR INHIBITORS TO ENHANCE T CELL IMMUNE RESPONSES |
| 12/18/2014 | US20140370058 One dose vaccination against mycoplasma infections of pigs |
| 12/18/2014 | US20140370056 Mucosal Vaccine Using Cationic Nanogel |
| 12/18/2014 | US20140370055 Compositions and methods for vaccinating against hsv-2 |
| 12/18/2014 | US20140370054 Methods for inhibition of type 1 diabetes |
| 12/18/2014 | US20140370053 Adjuvant-sparing multi-dose influenza vaccination regimen |
| 12/18/2014 | US20140370052 Inhibitors of sialoadhesin for the treatment of diseases caused by enveloped viruses |
| 12/18/2014 | US20140370050 Piv5 as oncolytic agent |
| 12/18/2014 | US20140370049 Method for formulating a vaccine containing at least two antigens capable of adsorbing onto aluminium oxyhydroxide |
| 12/18/2014 | US20140370042 Stabilized Antiviral Fusion Helices |
| 12/18/2014 | US20140370041 Compositions and methods for treating influenza |
| 12/18/2014 | US20140370039 Il-12 immunotherapy for cancer |
| 12/18/2014 | US20140370036 COMPOSITIONS OF, AND METHODS FOR, ALPHA-1 ANTITRYPSIN FcFUSION MOLECULES |
| 12/18/2014 | US20140370026 Cytomegalovirus Surface Protein Complex For Use in Vaccines and as a Drug Target |
| 12/18/2014 | US20140370025 Uses of mammalian cytokines and agonists; related reagents |
| 12/18/2014 | US20140370012 Fusion proteins comprising igg2 hinge domains |
| 12/18/2014 | US20140370010 Treatment of leukemias and chronic myeloproliferative diseases with antibodies to epha3 |
| 12/18/2014 | US20140370009 Therapeutic nanoparticles and methods of use thereof |
| 12/18/2014 | US20140370002 Methods for the treatment of gout |
| 12/18/2014 | US20140370000 Stabilization of immunoglobulins through aqueous formulation with histidine at weak acidic to neutral ph |
| 12/18/2014 | US20140369997 Pharmaceutical composition for a foaming eye drop |
| 12/18/2014 | US20140369957 Combination of growth factors, cytokines, antibacterial/antiviral factors, stem cell stimulating factors, complement proteins c3a/c4a, immunoglobulins and chemotactic factors |